Paulo Martins MD, PhD, FAST, FEBS, FACS is a Transplant Surgeon and the lead of the Transplantation Lab. He is an associate Professor of Surgery and Adjunct Prof of Pathology at the University of Oklahoma. He graduated from the Federal University of Bahia in Brazil, completed a PhD in transplant immunology at the University of Berlin, and a transplant surgery fellowship at Harvard University (MGH). He is a member of the Sigma Xi Scientific Research Honor Society, Alpha Omega Alpha honor society. He was the previous chair of the International Liver Transplant Society Basic and Translational Science committee and current chair of the American Society of Transplantation Organ Preservation and Recovery committee. He is in the top 2% World Scientist list from Elsevier/Stanford University.Pedro Baptista, PharmD, PhD, Marie Curie Alumni, is a Senior ARAID Researcher at IIS Aragon, Zaragoza, Spain, where he directs the Laboratory of Organ Bioengineering and Regenerative Medicine. He serves as a Visiting Professor of Biomedical Engineering at Universidad Carlos III de Madrid. Dr. Baptista earned his Pharmacy Degree from the University of Lisbon and completed his PhD training at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, USA. He is Secretary General of the European Society of Artificial Organs (ESAO) and Chair of the European Association for the Study of the Liver (EASL) Regenerative Hepatology Consortium. Dr. Baptista has published extensively in high-impact journals on organ bioengineering, organoids, and regenerative hepatology, holds four patents, and has successfully spun off several related technologies into companies.

• Section I: The liver and liver diseases1. Prevalence of liver disease around the worldHelena Cortez-Pinto, Ana Craciun, Ricardo Crespo and Sofia Carvalhana2. Viral hepatitisJean-Charles Duclos-Vallee3. Non-alcoholic steatohepatitisMiguel Pinheiro, Marta B. Afonso and Cecılia M.P. Rodrigues4. Alcoholic liver diseaseZachary DeVore, Philip McNamara, Dimitri Belkin, Naveen Ganjoo and Deepika Devuni5. Liver fibrosis and cirrhosisPhilipp Schwabl, Margarita Papatheodoridi and Massimo Pinzani6. Biomarkers in liver disease and transplantation: Outlook for precision medicineRuslan A. Mammadov, Vincent T. Janmaat, Cornelia J. Verhoeven, Jan N.M. IJzermans,Maikel P. Peppelenbosch, Luc J.W. van der Laan and Henk P. RoestSection II: Liver transplantation7. Living donor liver transplantationHan Li, Paulo Martins, Babak Mavahedi and Adel Bozorgzadeh8. Small-for-size syndrome in liver transplantationMartin Montenovo9. Clinical trials design and endpoints in liver transplantationRichard W. Laing, Amanda P.C.S. Boteon and Yuri L. Boteon10. Oncologic liver transplantation: Transplant oncologyTaizo Hibi11. Management of hepatocellular carcinomaAlejandro Serrablo, Alejandra Utrillas-Fornals, Pablo Parra, Luis Tejedor and Leyre SerrabloSection III: Cell transplantation12. Human hepatocyte transplantationJessica Nulty, Hanish Anand and Anil Dhawan13. Mesenchymal stem cell transplantationM. Najimi, G. de Bodt, G. Jannone and E.M. Sokal14. Biliary tree stem cell transplantationSavino Paradiso, Federica Cremisini, Matteo Franchitto, Guido Carpino and Vincenzo CardinaleSection IV: Liver preservation and machine perfusion15. General principles of organ preservation in liver transplantationS.H. Abbas, F. Dengu and P.J. Friend16. Ischemia-reperfusion injuryJoan Rosello Catafau and Arnau Panisello RoselloSection V: Regenerative medicine in liver disease and transplantation17. Liver regenerationUdayan Apte18. Whole-liver bioengineering: The future of transplantation medicineDiogo Marques, Natalia Sanchez Romero, Sandra Meliton Barbancho, Alvaro Blanes Rodriguez, Pilar Sainz de la Masa Arnal, Helen Almeida, Pablo Royo Dachary and Pedro M. Baptista19. Nanotechnology application in liver transplantationChristine G. Yao20. Acute liver failure and bioreactors/liver assist devicesManon Guillet, Claire de Lartigue, Ulysse Pereira, Marwa Hussein, Mattia Pasqua and Cecile Legallais21. Hepatobiliary organoids and large-scale expansion for regenerative therapiesKerstin Schneeberger, Sara Morini and Bart Spee22. Liver agingEric Felli and Jordi Gracia-Sancho

Paulo Martins MD, PhD, FAST, FEBS, FACS is a Transplant Surgeon and the lead of the Transplantation Lab. He is an associate Professor of Surgery and Adjunct Prof of Pathology at the University of Oklahoma. He graduated from the Federal University of Bahia in Brazil, completed a PhD in transplant immunology at the University of Berlin, and a transplant surgery fellowship at Harvard University (MGH). He is a member of the Sigma Xi Scientific Research Honor Society, Alpha Omega Alpha honor society. He was the previous chair of the International Liver Transplant Society Basic and Translational Science committee and current chair of the American Society of Transplantation Organ Preservation and Recovery committee. He is in the top 2% World Scientist list from Elsevier/Stanford University.Pedro Baptista, PharmD, PhD, Marie Curie Alumni, is a Senior ARAID Researcher at IIS Aragon, Zaragoza, Spain, where he directs the Laboratory of Organ Bioengineering and Regenerative Medicine. He serves as a Visiting Professor of Biomedical Engineering at Universidad Carlos III de Madrid. Dr. Baptista earned his Pharmacy Degree from the University of Lisbon and completed his PhD training at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, USA. He is Secretary General of the European Society of Artificial Organs (ESAO) and Chair of the European Association for the Study of the Liver (EASL) Regenerative Hepatology Consortium. Dr. Baptista has published extensively in high-impact journals on organ bioengineering, organoids, and regenerative hepatology, holds four patents, and has successfully spun off several related technologies into companies.

• Section I: The liver and liver diseases1. Prevalence of liver disease around the worldHelena Cortez-Pinto, Ana Craciun, Ricardo Crespo and Sofia Carvalhana2. Viral hepatitisJean-Charles Duclos-Vallee3. Non-alcoholic steatohepatitisMiguel Pinheiro, Marta B. Afonso and Cecılia M.P. Rodrigues4. Alcoholic liver diseaseZachary DeVore, Philip McNamara, Dimitri Belkin, Naveen Ganjoo and Deepika Devuni5. Liver fibrosis and cirrhosisPhilipp Schwabl, Margarita Papatheodoridi and Massimo Pinzani6. Biomarkers in liver disease and transplantation: Outlook for precision medicineRuslan A. Mammadov, Vincent T. Janmaat, Cornelia J. Verhoeven, Jan N.M. IJzermans,Maikel P. Peppelenbosch, Luc J.W. van der Laan and Henk P. RoestSection II: Liver transplantation7. Living donor liver transplantationHan Li, Paulo Martins, Babak Mavahedi and Adel Bozorgzadeh8. Small-for-size syndrome in liver transplantationMartin Montenovo9. Clinical trials design and endpoints in liver transplantationRichard W. Laing, Amanda P.C.S. Boteon and Yuri L. Boteon10. Oncologic liver transplantation: Transplant oncologyTaizo Hibi11. Management of hepatocellular carcinomaAlejandro Serrablo, Alejandra Utrillas-Fornals, Pablo Parra, Luis Tejedor and Leyre SerrabloSection III: Cell transplantation12. Human hepatocyte transplantationJessica Nulty, Hanish Anand and Anil Dhawan13. Mesenchymal stem cell transplantationM. Najimi, G. de Bodt, G. Jannone and E.M. Sokal14. Biliary tree stem cell transplantationSavino Paradiso, Federica Cremisini, Matteo Franchitto, Guido Carpino and Vincenzo CardinaleSection IV: Liver preservation and machine perfusion15. General principles of organ preservation in liver transplantationS.H. Abbas, F. Dengu and P.J. Friend16. Ischemia-reperfusion injuryJoan Rosello Catafau and Arnau Panisello RoselloSection V: Regenerative medicine in liver disease and transplantation17. Liver regenerationUdayan Apte18. Whole-liver bioengineering: The future of transplantation medicineDiogo Marques, Natalia Sanchez Romero, Sandra Meliton Barbancho, Alvaro Blanes Rodriguez, Pilar Sainz de la Masa Arnal, Helen Almeida, Pablo Royo Dachary and Pedro M. Baptista19. Nanotechnology application in liver transplantationChristine G. Yao20. Acute liver failure and bioreactors/liver assist devicesManon Guillet, Claire de Lartigue, Ulysse Pereira, Marwa Hussein, Mattia Pasqua and Cecile Legallais21. Hepatobiliary organoids and large-scale expansion for regenerative therapiesKerstin Schneeberger, Sara Morini and Bart Spee22. Liver agingEric Felli and Jordi Gracia-Sancho

Paulo Martins MD, PhD, FAST, FEBS, FACS is a Transplant Surgeon and the lead of the Transplantation Lab. He is an associate Professor of Surgery and Adjunct Prof of Pathology at the University of Oklahoma. He graduated from the Federal University of Bahia in Brazil, completed a PhD in transplant immunology at the University of Berlin, and a transplant surgery fellowship at Harvard University (MGH). He is a member of the Sigma Xi Scientific Research Honor Society, Alpha Omega Alpha honor society. He was the previous chair of the International Liver Transplant Society Basic and Translational Science committee and current chair of the American Society of Transplantation Organ Preservation and Recovery committee. He is in the top 2% World Scientist list from Elsevier/Stanford University.Pedro Baptista, PharmD, PhD, Marie Curie Alumni, is a Senior ARAID Researcher at IIS Aragon, Zaragoza, Spain, where he directs the Laboratory of Organ Bioengineering and Regenerative Medicine. He serves as a Visiting Professor of Biomedical Engineering at Universidad Carlos III de Madrid. Dr. Baptista earned his Pharmacy Degree from the University of Lisbon and completed his PhD training at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, USA. He is Secretary General of the European Society of Artificial Organs (ESAO) and Chair of the European Association for the Study of the Liver (EASL) Regenerative Hepatology Consortium. Dr. Baptista has published extensively in high-impact journals on organ bioengineering, organoids, and regenerative hepatology, holds four patents, and has successfully spun off several related technologies into companies.

• Section I: The liver and liver diseases1. Prevalence of liver disease around the worldHelena Cortez-Pinto, Ana Craciun, Ricardo Crespo and Sofia Carvalhana2. Viral hepatitisJean-Charles Duclos-Vallee3. Non-alcoholic steatohepatitisMiguel Pinheiro, Marta B. Afonso and Cecılia M.P. Rodrigues4. Alcoholic liver diseaseZachary DeVore, Philip McNamara, Dimitri Belkin, Naveen Ganjoo and Deepika Devuni5. Liver fibrosis and cirrhosisPhilipp Schwabl, Margarita Papatheodoridi and Massimo Pinzani6. Biomarkers in liver disease and transplantation: Outlook for precision medicineRuslan A. Mammadov, Vincent T. Janmaat, Cornelia J. Verhoeven, Jan N.M. IJzermans,Maikel P. Peppelenbosch, Luc J.W. van der Laan and Henk P. RoestSection II: Liver transplantation7. Living donor liver transplantationHan Li, Paulo Martins, Babak Mavahedi and Adel Bozorgzadeh8. Small-for-size syndrome in liver transplantationMartin Montenovo9. Clinical trials design and endpoints in liver transplantationRichard W. Laing, Amanda P.C.S. Boteon and Yuri L. Boteon10. Oncologic liver transplantation: Transplant oncologyTaizo Hibi11. Management of hepatocellular carcinomaAlejandro Serrablo, Alejandra Utrillas-Fornals, Pablo Parra, Luis Tejedor and Leyre SerrabloSection III: Cell transplantation12. Human hepatocyte transplantationJessica Nulty, Hanish Anand and Anil Dhawan13. Mesenchymal stem cell transplantationM. Najimi, G. de Bodt, G. Jannone and E.M. Sokal14. Biliary tree stem cell transplantationSavino Paradiso, Federica Cremisini, Matteo Franchitto, Guido Carpino and Vincenzo CardinaleSection IV: Liver preservation and machine perfusion15. General principles of organ preservation in liver transplantationS.H. Abbas, F. Dengu and P.J. Friend16. Ischemia-reperfusion injuryJoan Rosello Catafau and Arnau Panisello RoselloSection V: Regenerative medicine in liver disease and transplantation17. Liver regenerationUdayan Apte18. Whole-liver bioengineering: The future of transplantation medicineDiogo Marques, Natalia Sanchez Romero, Sandra Meliton Barbancho, Alvaro Blanes Rodriguez, Pilar Sainz de la Masa Arnal, Helen Almeida, Pablo Royo Dachary and Pedro M. Baptista19. Nanotechnology application in liver transplantationChristine G. Yao20. Acute liver failure and bioreactors/liver assist devicesManon Guillet, Claire de Lartigue, Ulysse Pereira, Marwa Hussein, Mattia Pasqua and Cecile Legallais21. Hepatobiliary organoids and large-scale expansion for regenerative therapiesKerstin Schneeberger, Sara Morini and Bart Spee22. Liver agingEric Felli and Jordi Gracia-Sancho